Hidradenitis Suppurativa Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Hidradenitis Suppurativa remains an active clinical development field. Clinical competition is shifting from broad immunosuppression toward pathway-selective control, durable remission and treatment strategies that reduce steroid exposure without trading away safety. The PatSnap evidence set used here contains 148 matched trial records and 192 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07690319 | Intervention not normalized | Not Applicable; Not yet recruiting | Novartis Pharmaceuticals Canada, Inc. | Geography not listed | Proportion of Patients Achieving 55% Reduction From Baseline in International Hidradenitis Suppurativa Severity Scoring System (IHS4-55) at 6 and 12 Months (6 and 12 months) | 2027-03-15 |
| NCT07689188 | Roflumilast | Phase 2; Not yet recruiting | Sponsor not listed | United States | Change from Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16 (Baseline and Week 16) | 2028-03-10 |
| ChiCTR2600127335 | Intervention not normalized | Not Applicable; Not yet recruiting | Wuhan Xiehe Hospital Tower | China | Disease history: Disease course, time of diagnosis, family history; (upon presentation to the hospital); Severity of the disease: Hurley stage, IHS4 score, VAS score; (upon presentation to the hospital) | 2026-08-01 |
| NCT07668713 | Intervention not normalized | Phase 1; Not yet recruiting | Centre Hospitalier Universitaire de Clermont Ferrand | France | Improvement of at least 55% in the IHS4 score (International Hidradenitis Suppurativa Severity Score System) (At week 12 post FMT) | 2030-06-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Lunsayil LTE: An Extension Trial Assessing Long-term Spesolimab Treatment in Patients With Hidradenitis Suppurativa (HS) (Phase 2/3): the indexed record reports Occurrence of Treatment Emergent Adverse Events (TEAE) up to the End of Maintenance Treatment Period = 3 Participants; Occurrence of Treatment Emergent Adverse Events (TEAE) up to the End of Maintenance Treatment Period = 5 Participants; Occurrence of Treatment Emergent Adverse Events (TEAE) up to the End of Maintenance Treatment Period = 6 Participants.
- INJECTION SITE PAIN AND ADHERENCE IN PATIENTS SWITCHING FROM REFERENCE ADALIMUMAB TO AVT02 - EASE PAIN TRIAL (FULL ANALYSIS) (Phase 4): the indexed record reports Adherence rate = 93.4 %.
- Association Between Bimekizumab’s Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II (Phase 3): the indexed record reports DLQI(0/1) = 17.2 %; DLQI(0/1) = 19.6 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Roflumilast (Approved; PDE4). Company & Deal Intelligence records identify sponsor context for Novartis Pharmaceuticals Canada, Inc., Wuhan Xiehe Hospital Tower, Centre Hospitalier Universitaire de Clermont Ferrand. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Standard definitions for steroid-free remission and durable disease control.
- Head-to-head trials against current targeted standards, not placebo alone.
- Biomarker strategies that distinguish mechanistic responders before prolonged treatment.
- Long-term infection, malignancy and immune-reconstitution follow-up.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Hidradenitis Suppurativa has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
